China
4D Molecular Therapeutics and Otsuka Form $471 Million Partnership to Advance 4D-150 Gene Therapy Across Asia-Pacific
4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for dev...
November 04, 2025 | News
4D Molecular Therapeutics and Otsuka Form $471 Million Partnership to Advance 4D-150 Gene Therapy Across Asia-Pacific
4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for dev...
November 04, 2025 | News
NovaBridge Subsidiary Visara Assigns Exclusive License for VIS-101 to Everest Medicines to Advance Treatment for Wet AMD Across Asia
NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet...
November 03, 2025 | News
JW Therapeutics Expands Strategic Collaboration with Regeneron to Advance TCR-T Cell Therapy and Platform Innovation
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunother...
November 03, 2025 | News
Shanghai Zhimeng Biopharma Begins Phase 2/3 Trial of Next-Generation Potassium Channel Opener for ALS
Previously (in July 2025), CB03-154 received approval from the China Center for Drug Evaluation (CDE) to conduct the ALS phase 2/3 adaptive clin...
November 03, 2025 | News
Everest Medicines Expands into Ophthalmology with Exclusive License for VIS-101 from Visara, a NovaBridge Subsidiary
Everest Medicines announced that it has acquired an exclusive license with Visara, Inc. (“Visara”), a subsidiary of NovaBridge Biosciences (for...
October 31, 2025 | News
Starna Therapeutics Secures Over RMB 300 Million in Series B Financing to Accelerate in vivo CAR-T Innovation
Starna Therapeutics, a pioneering biotechnology company developing next-generation RNA and in vivo CAR-T therapies, today announced the successful closing ...
October 30, 2025 | News
Harbour BioMed Unveils Generative AI HCAb Model to Redefine Antibody Discovery and Development
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immu...
October 29, 2025 | News
Pharmaron to Acquire Majority Stake in Biortus Biosciences to Strengthen Structural Biology and AI-Driven Drug Discovery Capabilities
Pharmaron Beijing Co., Limited announced that it has entered into a definitive Share Purchase Agreement to acquire 82.54% equity interest of Biortus ...
October 29, 2025 | News
OncoC4 and BioNTech’s Gotistobart Receives Breakthrough Therapy Designation in China for Squamous Non-Small Cell Lung Cancer
Designation granted for gotistobart (BNT316/ONC392) for the treatment of patients with squamous non-small cell lung cancer (sqNSCLC), an aggressive subtype...
October 28, 2025 | News
Nielsen BioSciences and Maruho Expand Licensing Agreement for CANDIN Across Key Asian Markets
Expansion of licensing agreement extends CANDIN’s development to key Asian growth markets including China, South Korea and Taiwan--and broadens the...
October 27, 2025 | News
Alphamab Oncology Doses First Patient in Global First PD-L1/αvβ6 Bispecific ADC Clinical Trial
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I...
October 27, 2025 | News
EMA Grants Orphan Drug Designation to Ribo’s RBD1016 for Treatment of Hepatitis D Virus Infection
Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), announced that the European Medicines Agency (EMA) has granted O...
October 27, 2025 | News
METiS TechBio’s AI-Designed MTS-004 Meets Phase III Success in China, Targeting Pseudobulbar Affect
MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) METiS TechBio, a global leader in AI-driven nanodelivery and formulatio...
October 24, 2025 | News
Most Read
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
